Novartis Says Only 3,000 Pollen Allergy Patients Used Xolair This Season, Less than 10% of Re-Pricing Line

Novartis’ antibody drug Xolair (omalizumab) was battered by a 37.3% price slash in April last year as its label expansion into pollen allergy triggered a new re-pricing rule. Now, it turns out that the number of patients treated with the...read more